

10/816, 298

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 20:05:12 ON 14 DEC 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 20:05:29 ON 14 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 DEC 2006 HIGHEST RN 915360-23-5

DICTIONARY FILE UPDATES: 13 DEC 2006 HIGHEST RN 915360-23-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

*** YOU HAVE NEW MAIL ***

=>


Uploading C:\Program Files\Stnexp\Queries\10816298.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 20:05:52 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3826866 TO ITERATE

24.2% PROCESSED 926147 ITERATIONS 17385 ANSWERS

26.1% PROCESSED 1000000 ITERATIONS 19421 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.20

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 3826866 TO 3826866
PROJECTED ANSWERS: 73504 TO 75138

L2 19421 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
166.94	167.15

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 20:06:19 ON 14 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Dec 2006 VOL 145 ISS 25
FILE LAST UPDATED: 13 Dec 2006 (20061213/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12

L3 1226 L2

=> s 13 and label (8a) base

62877 LABEL

689309 BASE

358 LABEL (8A) BASE

L4 1 L3 AND LABEL (8A) BASE

=> d 14 bib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:837304 CAPLUS

DN 141:296250

TI Preparation of nucleotide analogs with six membered rings and their incorporation into nucleic acids

IN Bergmann, Frank; Donner, Horst; Von der Eltz, Herbert; Heindl, Dieter; Herdewijn, Piet

PA Roche Diagnostics G.m.b.H., Germany; F.Hoffmann-La Roche A.-G.

SO Eur. Pat. Appl., 44 pp.


CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1466919	A1	20041013	EP 2004-7907	20040401
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CA 2463719	AA	20041005	CA 2004-2463719	20040331
	US 2005004078	A1	20050106	US 2004-816298	20040401
	JP 2004339202	A2	20041202	JP 2004-110224	20040402
	CN 1569870	A	20050126	CN 2004-10045158	20040405
PRAI	EP 2003-7844	A	20030405		
OS	MARPAT 141:296250				
GI					



AB Title compds. (I; L = linker; B = heterocyclic base; R1 = protecting group, label solid phase, H; R2 = H, OR6; R3 = protecting group, linker covalently coupled to a solid phase, phosphoramidite, phosphonate, triphosphate; R4 = H, OH, alkyl, halo, OR5, SR5, NR5R5a, label linker covalently coupled to a solid phase; R6 = H, protecting group, linking moiety coupled to a solid phase, phosphoramidite, phosphonate; R5 = alkyl, alkenyl, alkynyl, aryl, acyl, protecting group, H; R5a, R5b = H, alkyl, alkenyl, alkynyl, aryl, acyl; Y = O, S, NR5, CR5aR5b; dotted line = optional double bond), were prepared Thus, 1,5-anhydro-2-(5-(6-biotin-amido-hexanoate amido-allyl)-uracil)-2,3-dideoxy-D-arabino-hexitol-6-triphosphate was prepared for incorporation into nucleic acids for use in PCR (polymerase chain reaction)-based diagnostics.

IT 764657-94-5P



RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of labeled nucleotides, capable of oligomerization, for uses in nucleic acid hybridization and PCR diagnostic studies)

RN 764657-94-5 CAPLUS

CN D-arabino-Hexitol, 6-O-[bis(4-methoxyphenyl)phenylmethyl]-1,5-anhydro-2,3-dideoxy-2-[5-[3-[[6-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]hexyl]amino]-3-oxo-1-propenyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]-, 4-[2-cyanoethyl bis(1-methylethyl)phosphoramidite] (9CI) (CA INDEX NAME)



Absolute stereochemistry.

Double bond geometry unknown.



IT 764657-93-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of labeled nucleotides, capable of oligomerization, for uses in
 nucleic acid hybridization and PCR diagnostic studies)
 RN 764657-93-4 CAPLUS
 CN D-arabino-Hexitol, 6-O-[bis(4-methoxyphenyl)phenylmethyl]-1,5-anhydro-2,3-
 dideoxy-2-[5-[3-[[6-[[9H-fluoren-9-ylmethoxy)carbonyl]amino]hexyl]amino]-
 3-oxo-1-propenyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



=> d his

(FILE 'HOME' ENTERED AT 20:05:12 ON 14 DEC 2006)

FILE 'REGISTRY' ENTERED AT 20:05:29 ON 14 DEC 2006

L1 STRUCTURE UPLOADED

L2 19421 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:06:19 ON 14 DEC 2006

L3 1226 S L2

L4 1 S L3 AND LABEL (8A) BASE

=> s 3 and label?

6758686 3

442428 LABEL?

L5 148199 3 AND LABEL?

=> s 13 and label? (10a) base

442428 LABEL?

689309 BASE

1953 LABEL? (10A) BASE

L6 1 L3 AND LABEL? (10A) BASE

=> s 16 not 15

L7 0 L6 NOT L5

=> s 13 and label?

442428 LABEL?

L8 15 L3 AND LABEL?

=> s 18 not 16

L9 14 L8 NOT L6

=> dup rem 19

PROCESSING COMPLETED FOR L9

L10 14 DUP REM L9 (0 DUPLICATES REMOVED)

=> d 110 bib abs 1-14

L10 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:699763 CAPLUS

DN 145:145535

TI Preparation of 11C-labeled benzyl-lactam compounds and their use
as imaging agents

IN Helal, Christopher John; Antoni, Gunnar; Langstrom, Bengt; Sheng, Jia Zhi;
Jaynes-Sobolove, Susan Beth; McCarthy, Timothy John

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006075226	A1	20060720	WO 2006-IB28	20060111
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2005-643453P	P	20050113		
OS	MARPAT 145:145535				
GI					


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to 11C-labeled compds. I [X = CH or N; Y = C(OR1)(R2)2 or N(R3)2; R1 = H or alkyl; R2 independently = alkyl or both R2 groups together form (CH2)n where n = 2-7; R3 independently = alkyl or both groups together form (CH2)O(CH2)2, (CH2)(NR4)(CH2)2, or (CH2)m where m = 2-7; R4 = H or Me; * signifies a chiral carbon, wherein the carbon is a racemate, an (R)-enantiomer, an (S)-enantiomer, or a mixture thereof], their preparation, compns. comprising an effective amount of a 11C-labeled compound, and the use of a 11C-labeled compound as a radiopharmaceutical for positron emission tomog. Thus, e.g., II was prepared by resolution of 1-[4-(1-methoxy-1-methylethyl)phenyl]-3-(2-piperazin-1-yl)pyrrolidin-2-one (preparation given) to the (R)-enantiomer followed by N-methylation with 11CH3I.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:366881 CAPLUS
DN 144:412478
TI Preparation of pyrrolo-pyridine, pyrrolo-pyrimidine and related
heterocyclic compounds as ligands of C5a receptors
IN Yuan, Jun; Hrnciar, Peter; Guo, Qin; Maynard, George D.
PA Neurogen Corporation, USA
SO PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006042102	A2	20060420	WO 2005-US36126	20051005
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-616311P	P	20041005		
OS	MARPAT 144:412478				
GI					



AB The title compds. I [E = a bond, O, SOm, NR6, CR6R7; R6, R7 = H, alkyl; m = 0-2; Ar = (un)substituted Ph, 1- and 2-naphthyl, heteroaryl; 5-membered ring containing Z1 and Z2 atoms contains exactly one heteroatom; Z1 = CR1 or NR11; Z3 = CR3, NR31; R1, R11 = alkyl, cycloalkyl, aryl, etc.; R2 = H, halo, OH, etc.; R3, R31 = alkyl, haloalkyl, alkoxy, etc.; Z4 = NR, CR4; R is absent or oxygen; R4, R5 = H, halo, OH, etc.] which are ligands of C5a receptors, were prepared and formulated. E.g., a 2-step synthesis of II, starting from 2-chloro-4-methyl-5-nitropyridine and 2,6-diethylphenylboronic acid, was given. Preferred pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compds. of the invention (I) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compns. comprising such compds. I, and to the use of such compds. in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compds., which are useful as probes for the localization of C5a receptors.

L10 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:164346 CAPLUS
 DN 144:234605
 TI Fluorescein fluorescent labeling agents
 IN Nagano, Tetsuo; Urano, Yasuteru; Mineno, Tomoko; Ueno, Tasuku
 PA Daiichi Pure Chemicals Co., Ltd., Japan
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006019105	A1	20060223	WO 2005-JP14983	20050817
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-601986P	P	20040817		
OS	MARPAT 144:234605				
GI					




AB The fluorescent labeling agent exhibiting high fluorescence in a state bound to the substrate to be labeled, contains I (R1-4 = H, a monovalent substituent; R5 = H, a monovalent group exclusive of carboxy and sulfo; R6, R7 = H, halo; and R8 = H, alkylcarbonyl, alkylcarbonyloxymethyl) bonded with a labeling compound
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:1001055 CAPLUS
 TI Synthesis of new, BODIPY-based sensors and labels
 AU Kalai, Tamas; Hideg, Kalman
 CS Institute of Organic and Medicinal Chemistry, University of Pecs, Pecs, H-7602, Hung.
 SO Tetrahedron (2006), 62(44), 10352-10360
 CODEN: TETRAB; ISSN: 0040-4020

PB Elsevier Ltd.
 DT Journal
 LA English
 AB New, 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) dye based thiol-reactive fluorescent label, fluorescent amino acid, and fluoroionophore compds. with 540-560 nm emission are described. Combination of a BODIPY dye with a nitronyl nitroxide or an imino nitroxide or a bifunctional pyrroline nitroxide furnished a nitric oxide, a redox sensitive mol. and a double (spin and fluorescence) label, resp.

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:660686 CAPLUS
 DN 145:284874
 TI Synthesis of Trifluoromethylaryl Diazirine and Benzophenone Derivatives of Etomidate that Are Potent General Anesthetics and Effective Photolabels for Probing Sites on Ligand-Gated Ion Channels
 AU Husain, S. Shaukat; Nirthanan, Selvanayagam; Ruesch, Dirk; Solt, Ken; Cheng, Qi; Li, Guo-Dong; Arevalo, Enrique; Olsen, Richard W.; Raines, Douglas E.; Forman, Stuart A.; Cohen, Jonathan B.; Miller, Keith W.
 CS Department of Anesthesia and Critical Care, Massachusetts General Hospital, Boston, MA, 02114, USA
 SO Journal of Medicinal Chemistry (2006), 49(16), 4818-4825
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 GI



AB To locate the binding sites of general anesthetics on ligand-gated ion channels, two derivs. of the i.v. general anesthetic etomidate (2-Et 1-(phenylethyl)-1H-imidazole-5-carboxylate), in which the 2-Et group has been replaced by photoactivable groups based on either aryl diazirine or benzophenone chemical, have been synthesized and characterized pharmacol. TDBzl-etomidate (I) and BzBzl-etomidate (II) are both potent general anesthetics with half-effective anesthetic concns. of 700 and 220 nM, resp. Both agents resembled etomidate in enhancing currents elicited by low concns. of GABA on heterologously expressed GABAA receptors and in

shifting the GABA concentration-response curve to lower concns. They also allosterically enhanced the binding of flunitrazepam to mammalian brain GABAA receptors. Both agents were also effective and selective photolabels, photoincorporating into some, but not all, subunits of the Torpedo nicotinic acetylcholine receptor to a degree that was allosterically regulated by an agonist or a noncompetitive inhibitor. Thus, they have the necessary pharmacol. and photochem. properties to be useful in identifying the site of etomidate-induced anesthesia.

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:453922 CAPLUS
DN 145:117200
TI Design and synthesis of a biotin-tagged photoaffinity probe of paeoniflorin
AU Qiu, Wen-Wei; Xu, Jie; Liu, Da-Zhi; Li, Jing-Ya; Ye, Yang; Zhu, Xing-Zu; Li, Jia; Nan, Fa-Jun
CS Chinese National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Shanghai, 201203, Peop. Rep. China
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(12), 3306-3309
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 145:117200
AB A trifunctional probe (binding element-photoreactive group-affinity tag) of natural product paeoniflorin was designed and synthesized based on the previous primary structure-activity relationship. This new probe is a potential tool for labeling, purification, and identification of the target proteins.

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:34510 CAPLUS
DN 142:116014
TI Fluorophore compounds and their use in labeling biomolecules and biological structures
IN Moerner, William E.; Twieg, Robert J.; Kline, Douglas W.; He, Meng
PA Stanford University, USA
SO U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO
DT Patent
LA English


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005009109	A1	20050113	US 2003-604282	20030708
WO 2005005956	A2	20050120	WO 2004-US19825	20040621
WO 2005005956	A3	20050519		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2003-604282	A	20030708		

OS MARPAT 142:116014
 AB Fluorophore compds. and methods for their use are disclosed. The fluorophores contain a 2-dicyanomethylen-3-cyano-2,5-dihydrofuran (DCDHF) moiety and one or more donor groups conjugated to the 2-dicyanomethylen-3-cyano-2,5-dihydrofuran group (e.g., 3-cyano-2-dicyanomethylen-4-[4-(N,N-dihexylaminophenyl)]-5,5-dimethyl-2,5-dihydrofuran, DCDHF-6). The donor groups can contain atoms with free electron pairs such as oxygen, sulfur, nitrogen, or phosphorous. The fluorophore compds. can be used to label and detect biol. mols. and biol. structures either in vivo or in vitro.

L10 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1045033 CAPLUS
 DN 143:341743
 TI Development of novel synthetic substrates for N-acetylglucosamine transferase V
 IN Saji, Hideo; Mukai, Takahiro; Magata, Yasuhiro; Node, Satoru; Kato, Takahiro; Taniguchi, Naoyuki; Miyoshi, Hidetomo
 PA Nihon Medipysics Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 24 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2005263691	A2	20050929	JP 2004-78510	20040318
PRAI	JP 2004-78510		20040318		
OS	MARPAT 143:341743				
GI					



AB A group of novel radio-labeled substrates that can be working as glyco-chain-receptors for N-acetylglucosamine transferase V has been designed for the rapid and sensitive assay for the enzyme. The synthetic substrates in the group present general equation I (R1 .apprx. R3 are independently hydrogen, halogen or acetyl group and n = integer selectable among the nos. from 2 to 7, and isotope indicator X = 123I, 124I, 131I or most typically 125I). A substrate, IPGMG [2-(4-iodophenyl)ethyl-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→2)-O-α-D-mannopyranosyl-(1→6)-β-D-glucopyranoside] and its enzyme product IPGGMG were synthesized and the usefulness of IPGMG as the substrate for N-acetylglucosamine transferase V was exptl. demonstrated.

L10 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:614646 CAPLUS
 DN 143:281936
 TI Detection of 210kDa receptor protein for a leaf-movement factor by using novel photoaffinity probes
 AU Fujii, Tomohiko; Manabe, Yoshiyuki; Sugimoto, Takanori; Ueda, Minoru
 CS Department of Chemistry, Tohoku University, Aoba-ku, Sendai, 980-8578, Japan
 SO Tetrahedron (2005), 61(33), 7874-7893
 CODEN: TETRAB; ISSN: 0040-4020
 PB Elsevier B.V.
 DT Journal
 LA English
 AB Circadian rhythmic plant leaf-movement, called nyctinasty, is controlled by a time-course change in the internal concentration of the leaf-movement factor in the plant body. The authors revealed that specific binding proteins (210 and 180 kDa) for the leaf-movement factor, potassium lespedeazate, are contained in the plasma membrane of the plant motor cell by using novel synthetic photoaffinity probes. These proteins are localized on the motor cell in the plant body, and would be potential receptors for the leaf-movement factor to control the leaf-movement. The authors' study is a rare successful result of the detection of membrane receptors by using a synthetic photoaffinity probe designed on a biol. active natural product. And these results also advance a guideline for probe design towards successful photoaffinity labeling.

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:502326 CAPLUS
 DN 144:36456
 TI Development of highly potent D-glucosamine-based chiral fluorescent labeling reagents and a microwave-assisted β -selective glycosidation of a methyl glycoside reagent
 AU Ohnui, Hiroshi; Kato, Rumiko; Kodaira, Teruhisa; Shimizu, Hiroki; Akasaka, Kazuaki; Kitahara, Takeshi
 CS Graduate School of Life Sciences, Tohoku University, Sendai, 981-8555, Japan
 SO Bioscience, Biotechnology, and Biochemistry (2005), 69(5), 1054-1057
 CODEN: BBBIEJ; ISSN: 0916-8451
 PB Japan Society for Bioscience, Biotechnology, and Agrochemistry
 DT Journal
 LA English
 OS CASREACT 144:36456
 AB New chiral fluorescence labeling reagents having a 2,3-anthracenedicarboximide group from D-glucosamine were synthesized, and it was possible to introduce target alcs. at the anomeric positions of the reagents with β -selectivity by glycosidation. Especially, it was possible to use Me glycoside reagent as a glycosyl donor with a Lewis acid and microwave irradiation, and it gave selectively β -glycoside while the reaction without microwave irradiation gave α - and β -mixed glycosides. Those reagents showed very high chiral discrimination ability, and they made it possible to sep. the eight stereoisomers of 4,8,12,16-tetramethylheptadecanol by HPLC after derivatization.

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:428911 CAPLUS
 DN 141:7028
 TI Preparation of 3-substituted-6-aryl pyridines ligands of C5a receptors
 IN Hutchison, Alan; Yuan, Jun; Lee, Kyungae; Maynard, George; Chenard,

Bertrand L.; Liu, Nian; Guo, Qin; Guo, Zihong; Hrnaiar, Peter
 PA Neurogen Corporation, USA
 SO PCT Int. Appl., 366 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004043925	A2	20040527	WO 2003-US35694	20031107
	WO 2004043925	A3	20040805		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2504941	AA	20040527	CA 2003-2504941	20031107
	AU 2003291403	A1	20040603	AU 2003-291403	20031107
	US 2004158067	A1	20040812	US 2003-704364	20031107
	EP 1565452	A2	20050824	EP 2003-768799	20031107
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-425281P	P	20021108		
	WO 2003-US35694	W	20031107		
OS	MARPAT 141:7028				
GI					




AB The title compds. [I; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; A = OR₄, NR₄R₅, CR₆R₇, CHR₆R₇; R₁ = H, halo, NH₂, CN, etc.; R₂ = halo, CN, XR; R₃ = H, halo, OH, etc.; R₄ = alkyl, alkenyl, benzoisothiazolyl, etc.; R₅ = H, alkyl, alkenyl, etc.; R₆ = halo, OH, CN, etc.; R₇ = H, halo, OH, etc.; R₈ = H, halo, OH, etc.; R₉ = absent, H, halo, OH, etc.; X = a bond, O, CO, etc.; R = H, alkyl, alkenyl, etc.; R₁₇ = absent, O] which bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors, and therefore are useful in treating a variety of inflammatory, cardiovascular, and immune system disorders, were prepared and formulated. E.g., a multi-step synthesis of II is given. In

addition, the present invention provides labeled 3-substituted-6-aryl pyridines I, which are useful as probes for the localization of C5a receptors.

L10 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:1031107 CAPLUS
 DN 142:6752
 TI Synthesis of isotope-coded affinity tags containing a carbohydrate linker group and their use for protein analysis
 IN Lockhoff, Oswald; Schumacher, Andreas; Lerchen, Hans-Georg; Immler, Dorian
 PA Bayer Healthcare A.-G., Germany
 SO Ger. Offen., 39 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10322077	A1	20041202	DE 2003-10322077	20030515
PRAI	DE 2003-10322077		20030515		
OS	MARPAT 142:6752				
GI					



AB The invention concerns isotope-coded affinity markers, e.g. (I), containing a carbohydrate group(s) as linker between an affinity portion of the mol. and a label portion, for mass-spectrometric anal. of proteins, their production, use and kits containing them. Selected segments of the mol. can

contain isotopic atoms, e.g. ^{13}C in the carbohydrate or its alkyl link to the affinity group. Thus, biotin was reacted with 4-hydroxybenzaldehyde to form the left portion of I. To form the right portion of I, 2,3,4,6-tetra-O-acetyl- β -D-glucopyranose was reacted with acetonitrile, reduced to the free amine, and reacted with maleic acid anhydride. The left and right intermediates were then reacted to give I. Preparation of 2-bromoethyl β -D-glucopyranoside from β -D-glucopyranose- $^{13}\text{C}_6$ pentaacetate, as the right-half intermediate, as an example of isotopically labeled title compds., is given.

L10 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:686349 CAPLUS
 DN 141:375677
 TI The ion channel of F-ATP synthase is the target of toxic organotin compounds
 AU von Ballmoos, Christoph; Brunner, Josef; Dimroth, Peter
 CS ETH Zentrum, Institut fuer Mikrobiologie der Eidgenoessischen Technischen Hochschule, Zurich, CH-8092, Switz.
 SO Proceedings of the National Academy of Sciences of the United States of America (2004), 101(31), 11239-11244
 CODEN: PNASA6; ISSN: 0027-8424

PB National Academy of Sciences
DT Journal
LA English
OS CASREACT 141:375677

AB ATP is the universal energy currency of living cells, and the majority of it is synthesized by the F1F0 ATP synthase. Inhibitors of this enzyme are therefore potentially detrimental for all life forms. Tributyltin chloride (TBT-Cl) inhibits ATP hydrolysis by the Na⁺-translocating ATP synthase of *Ilyobacter tartaricus* or the H⁺-translocating counterpart of *Escherichia coli* with apparent K_i of 200 nM. To target the site of this inhibition, we synthesized a tritium-labeled derivative of TBT-Cl in which one of the Bu groups was replaced by a photoactivatable aryl diazirine residue. Upon illumination, subunit a of the ATP synthase becomes specifically modified, and this labeling is suppressed in the presence of the original inhibitor. In case of the Na⁺ ATP synthase, labeling is also suppressed in the presence of Na⁺ ions, suggesting an interference in Na⁺ or TBT-Cl binding to subunit a. This interference is corroborated by the protection of ATP hydrolysis from TBT-Cl inhibition by 105 mM Na⁺. TBT-Cl strongly inhibits Na⁺ exchange by the reconstituted *I. tartaricus* ATP synthase. Taken together these results indicate that the subunit a ion channel is the target site for ATPase inhibition by toxic organotin compds. An inhibitor interacting specifically with this site has not been reported previously.

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:767857 CAPLUS

DN 141:410774

TI Synthesis and reactions of paramagnetic aromatic aldehydes as useful synthetic building blocks

AU Kalai, Tamas; Kulcsar, Gyozo; Jeko, Jozsef; Osz, Erzsebet; Hideg, Kalman

CS Institute of Organic and Medicinal Chemistry, University of Pecs, Pecs, 7602, Hung.

SO Synthesis (2004), (13), 2115-2120

CODEN: SYNTBF; ISSN: 0039-7881

PB Georg Thieme Verlag

DT Journal


LA English

OS CASREACT 141:410774

AB Starting from 2,2,5-trimethyl-2-(4-formylphenyl)pyrrolidin-1-yloxy, a paramagnetic benzaldehyde, a benzophenone-type photoactivable spin label, paramagnetic warfarin and phenindione were synthesized. Nitration of protected benzylic alc. led to 2-nitrobenzyl methanethiosulfonate, a thiol specific spin label, and 2-nitro aldehyde, which was a key compound for paramagnetic indigo, salicylic acid and nifedipine.

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>



chain nodes :

14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 42 43 44 45 46

ring nodes :

2 3 4 5 6 7 8 9 10 11 12 13 34 35 36 37 38 39 40 41

chain bonds :

2-43 3-44 6-8 9-14 11-15 12-16 16-17 17-18 18-19 19-20 20-21 20-22 22-23 23-24 24-25 25-26 26-27 27-28
28-29 28-30 30-31 31-32 32-33 33-36 40-42 44-45 45-46

ring bonds :

2-3 2-7 3-4 4-5 5-6 6-7 8-9 8-13 9-10 10-11 11-12 12-13 34-35 34-38 34-41 35-36 36-37 37-38 38-39
39-40 40-41

exact/norm bonds :

2-3 2-7 2-43 3-4 4-5 5-6 6-7 6-8 8-9 8-13 9-10 9-14 10-11 11-12 11-15 12-13 18-19 19-20 20-21 26-27
27-28 28-29 34-35 34-38 34-41 35-36 36-37 37-38 38-39 39-40 40-41 40-42 44-45 45-46

exact bonds :

3-44 12-16 16-17 17-18 20-22 22-23 23-24 24-25 25-26 28-30 30-31 31-32 32-33 33-36

G1:C,O,S,N

Match level :

2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:CLASS15:CLASS
16:CLASS17:CLASS18:CLASS19:CLASS20:CLASS21:CLASS22:CLASS23:CLASS24:CLASS25:CLASS26:CLASS27:CLASS
28:CLASS29:CLASS30:CLASS31:CLASS32:CLASS33:CLASS34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom
40:Atom 41:Atom 42:CLASS43:CLASS44:CLASS45:CLASS46:CLASS

=>

Uploading C:\Program Files\Stnexp\Queries\108162982.str

L11 STRUCTURE UPLOADED

=> d l11

L11 HAS NO ANSWERS

L11 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l11 full

FULL SEARCH INITIATED 20:17:06 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L12 0 SEA SSS FUL L11

=>


Uploading C:\Program Files\Stnexp\Queries\108162983.str

L13 STRUCTURE UPLOADED

=> d l13

L13 HAS NO ANSWERS

L13 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l13 full

FULL SEARCH INITIATED 20:18:55 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 60 TO ITERATE

100.0% PROCESSED 60 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

L14 2 SEA SSS FUL L13

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

334.76

566.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-11.25

FILE 'CAPLUS' ENTERED AT 20:19:00 ON 14 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Dec 2006 VOL 145 ISS 25
FILE LAST UPDATED: 13 Dec 2006 (20061213/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s l14

L15 1 L14

=> d l15 bib abs hitstr

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:837304 CAPLUS
DN 141:296250
TI Preparation of nucleotide analogs with six membered rings and their incorporation into nucleic acids
IN Bergmann, Frank; Donner, Horst; Von der Eltz, Herbert; Heindl, Dieter; Herdewijn, Piet
PA Roche Diagnostics G.m.b.H., Germany; F.Hoffmann-La Roche A.-G.
SO Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1466919	A1	20041013	EP 2004-7907	20040401
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CA 2463719	AA	20041005	CA 2004-2463719	20040331
	US 2005004078	A1	20050106	US 2004-816298	20040401
	JP 2004339202	A2	20041202	JP 2004-110224	20040402
	CN 1569870	A	20050126	CN 2004-10045158	20040405
PRAI	EP 2003-7844	A	20030405		
OS	MARPAT 141:296250				
GI					



AB Title compds. (I; L = linker; B = heterocyclic base; R1 = protecting

group, label solid phase, H; R2 = H, OR6; R3 = protecting group, linker covalently coupled to a solid phase, phosphoramidite, phosphonate, triphosphate; R4 = H, OH, alkyl, halo, OR5, SR5, NR5R5a, label linker covalently coupled to a solid phase; R6 = H, protecting group, linking moiety coupled to a solid phase, phosphoramidite, phosphonate; R5 = alkyl, alkenyl, alkynyl, aryl, acyl, protecting group, H; R5a, R5b = H, alkyl, alkenyl, alkynyl, aryl, acyl; Y = O, S, NR5, CR5aR5b; dotted line = optional double bond), were prepared. Thus, 1,5-anhydro-2-(5-(6-biotin-amido-hexanoate amido-allyl)-uracil)-2,3-dideoxy-D-arabino-hexitol-6-triphosphate was prepared for incorporation into nucleic acids for use in PCR (polymerase chain reaction)-based diagnostics.

IT 764658-10-8P 764658-11-9P

RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of labeled nucleotides, capable of oligomerization, for uses in nucleic acid hybridization and PCR diagnostic studies)

RN 764658-10-8 CAPLUS


CN D-arabino-Hexitol, 1,5-anhydro-2,3-dideoxy-2-[5-[3-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]amino]-1-propenyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]-, 6-(tetrahydrogen triphosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 764658-11-9 CAPLUS


CN D-Altritol, 1,5-anhydro-2-deoxy-2-[5-[3-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]amino]-1-propenyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]-, 6-(tetrahydrogen triphosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



=>

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
17.99	584.84

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.75	-12.00

CA SUBSCRIBER PRICE

FILE 'BIOSIS' ENTERED AT 20:35:58 ON 14 DEC 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 20:35:58 ON 14 DEC 2006

FILE 'CAPLUS' ENTERED AT 20:35:58 ON 14 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 20:35:58 ON 14 DEC 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 20:35:58 ON 14 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s (pyranosyl? or cyclohexenyl?) (4a) nucleoside?
L16 142 (PYRANOSYL? OR CYCLOHEXENYL?) (4A) NUCLEOSIDE?

=> s l16 and label? (4a) base?
L17 0 L16 AND LABEL? (4A) BASE?

=> s l16 and label?
L18 8 L16 AND LABEL?

=> dup rem l18
PROCESSING COMPLETED FOR L18
L19 8 DUP REM L18 (0 DUPLICATES REMOVED)

=> d l19 bib abs 1-8

L19 ANSWER 1 OF 8 USPATFULL on STN
AN 2005:17310 USPATFULL
TI Oligomeric compounds for the modulation survivin expression
IN Hansen, Bo, Copenhagen K, DENMARK
Thru, Charlotte Albaek, Copenhagen K, DENMARK
Westergaard, Majken, Birkerod, DENMARK
Petersen, Kamille Dumong, Lejre, DENMARK
Wissenbach, Margit, Fredensborg, DENMARK
PI US 2005014712 A1 20050120
AI US 2004-776934 A1 20040210 (10)
PRAI US 2003-446372P 20030210 (60)
US 2003-523591P 20031119 (60)
DT Utility
FS APPLICATION
LREP EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205
CLMN Number of Claims: 152
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 11352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 2 OF 8 USPTAFULL on STN
AN 2004:315164 USPTAFULL
TI Oligomeric compounds for the modulation of ras expression
IN Hansen, Bo, Copenhagen K, DENMARK
Thue, Charlotte Albaek, Copenhagen K, DENMARK
Westergaard, Majken, Birkered, DENMARK
Petersen, Kamille Dumong, Lejre, DENMARK
Wissenbach, Margit, Fredensborg, DENMARK
PA Santaris Pharma A/S (non-U.S. corporation)
PI US 2004248840 A1 20041209
AI US 2004-776917 A1 20040210 (10)
PRAI DK 2003-1539 20031020
US 2003-446363P 20030210 (60)
DT Utility
FS APPLICATION
LREP Peter F. Corless, EDWARDS & ANGELL, LLP, P.O. Box 55874, Boston, MA, 02205
CLMN Number of Claims: 90
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 3922

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Oligonucleotides directed against the Ha-ras gene are provided for modulating the expression of Ha-ras. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Ha-ras. Methods of using these compounds for modulation of Ha-ras expression and for the treatment of diseases associated with either overexpression of Ha-ras, expression of mutated Ha-ras or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 3 OF 8 USPTAFULL on STN
AN 2004:307046 USPTAFULL
TI Oligomeric compounds for the modulation of thioredoxin expression
IN Hansen, Bo, Copenhagen K, DENMARK
Thue, Charlotte Albaek, Copenhagen K, DENMARK
Westergaard, Majken, Birkered, DENMARK
Petersen, Kamille Dumong, Lejre, DENMARK
Wissenbach, Margit, Fredensborg, DENMARK
PA Santaris Pharma A/S (non-U.S. corporation)
PI US 2004241717 A1 20041202
AI US 2004-776933 A1 20040210 (10)
PRAI US 2003-446374P 20030210 (60)

DT Utility
FS APPLICATION
LREP Peter F. Corless, EDWARDS & ANGELL, LLP, P. O. Box 55874, Boston, MA,
02205
CLMN Number of Claims: 90
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 3843

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Oligonucleotides directed against the TRX gene are provided for modulating the expression of TRX. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the TRX. Methods of using these compounds for modulation of TRX expression and for the treatment of diseases associated with either overexpression of TRX, expression of mutated TRX or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 4 OF 8 USPATFULL on STN
AN 2004:185060 USPATFULL
TI Modified nucleosides and nucleotides and use thereof
IN Chattopadhyaya, Jyoti, Uppsala, SWEDEN
PI US 2004142946 A1 20040722
AI US 2003-399951 A1 20030423 (10)
WO 2001-SE2484 20011109
DT Utility
FS APPLICATION
LREP YOUNG & THOMPSON, 745 SOUTH 23RD STREET 2ND FLOOR, ARLINGTON, VA, 22202
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 930

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to modified nucleotides and nucleosides and reagents to produce these. The modified nucleotides and nucleosides are assembled to larger oligonucleotides and oligonucleosides, which, for example, may be used for diagnostics of polymorphisms and for antisense therapy of various conditions. The oligonucleotides and oligonucleosides described in the invention have very good endonuclease resistance without compromising the RNA cleavage properties of RNase H wherein combinations of modifications with Y, Z, R or B are claimed: X=O or S, NH or NCH.sub.3, CH.sub.2 Or CH(CH.sub.3), Y=O, S, or NH or NCH.sub.3, CH.sub.2or CH(CH.sub.3); Z=O, S, or NH or NCH.sub.3, CH.sub.2 or CH(CH.sub.3); R=O or S, or NH or NCH.sub.3, CH.sub.2 or CH(CH.sub.3); B=A, C, G, T; 5-F/cl/BrU or --C, 6-thioguanine, 7-deazaguanine; α - or β -D- (or L)ribo, xylo, arabino or lyxo configuration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 5 OF 8 USPATFULL on STN
AN 2003:234845 USPATFULL
TI Method for producing a pyranosyl nucleic acid conjugate
IN Miculka, Christian, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Windhab, Norbert, Hattersheim, GERMANY, FEDERAL REPUBLIC OF
Brandstetter, Tilmann, Munchen, GERMANY, FEDERAL REPUBLIC OF
Burdinski, Gerhard, Nastatten, GERMANY, FEDERAL REPUBLIC OF
PA Nanogen Recognomics GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
(non-U.S. corporation)

PI US 6613894 B1 20030902
WO 9915540 19990401
AI US 2000-509010 20000320 (9)
WO 1998-EP5998 19980921
PRAI DE 1997-19741715 19970922
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: Crane, L. Eric
LREP O'Melveny & Myers LLP
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1940

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a process for the preparation of a pyranosyl nucleic acid of the formula (I) or of the formula (II) ##STR1##

The process for the preparation of the pyranosyl nucleic acid comprises (a) bonding the nucleoside to a solid support, (b) deprotecting the 3',4'-protected nucleoside, (c) reacting the reaction product from step (b) with a 3',4'-protected pyranosyl nucleoside phosphoramidite, repeating steps (b) and (c) one or more times to produce the desired length of nucleic acid, and coupling a biomolecule to the product of step (d). In a further step, the nucleic acid can be released from the solid support. In one embodiment, the biomolecule may be a DNA or RNA, where furanosyl nucleoside phosphoramidites are added to the pyranosyl nucleic acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 6 OF 8 USPATFULL on STN
AN 2001:223894 USPATFULL
TI Methods, procedures, and formats for using microelectronic array devices to perform multiplex immunoassay analyses
IN Windhab, Norbert, Hofheim, Germany, Federal Republic of
Heller, Michael J., Encinitas, CA, United States
Anderson, Richard R., Encinitas, CA, United States
Fiechtner, Michael D., Poway, CA, United States
Nova, Tina S., Rancho Santa Fe, CA, United States
Schweitzer, Markus, Frankfurt am Main, Germany, Federal Republic of
Sundquist, Alfred R., San Diego, CA, United States
Brucher, Christoph, Sulzbach, Germany, Federal Republic of
Orwick, Jill M., San Diego, CA, United States
Muller, Jochen, Diez, Germany, Federal Republic of
Raddatz, Stefan, Wiesbaden, Germany, Federal Republic of
Ackley, Donald E., Cardiff, CA, United States
Hamon, Christian, Frankfurt am Main, Germany, Federal Republic of
PI US 2001049111 A1 20011206
AI US 2001-783763 A1 20010214 (9)
RLI Continuation-in-part of Ser. No. US 1999-374338, filed on 13 Aug 1999, PENDING
DT Utility
FS APPLICATION
LREP LYON & LYON LLP, 633 WEST FIFTH STREET, SUITE 4700, LOS ANGELES, CA, 90071
CLMN Number of Claims: 112
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 2862

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to devices and methods for carrying out multi-step and multiplex immunoaffinity binding reactions in microscopic formats. In particular, these devices and methods allow the user to rapidly carry out multiple immunoassays in the same sample volume, and

to rapidly resolve the results of those immunoassays in an electronically assisted format. The assays may be further multiplexed in that several samples may be analyzed and visualized on the same microelectronic array. In addition, the methods and procedures of the invention allow the use of electronic stringency to further improve the specificity and accuracy of the immunoassays on the microelectronic array devices

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:395021 CAPLUS
DN 131:116450
TI Pyranosyl-RNA supramolecules containing non-hydrogen-bonding base-pairs
AU Hamon, Christian; Brandstetter, Tilmann; Windhab, Norbert
CS Department Bio-Organic Systems, Aventis Research Technologies,
Frankfurt/Main, D-65926, Germany
SO Synlett (1999), (Spec.), 940-944
CODEN: SYNLES; ISSN: 0936-5214
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 131:116450
AB Synthesis and properties of a pyranosyl-RNA nucleoside
using tryptamine as nucleobase is reported. Incorporation of this unit
into oligomers using standard phosphoramidite chemical yielded
self-complementary
and non-selfcomplementary oligonucleotide pairs. Thermal melting expts.
of these examples showed the sequence-dependent stabilizing
characteristics of the incorporated base in the sym. pairing constitution
with a standard Tm near that of a similar A-T-pair as well as pairing
selectivity with respect to non-sym. pairing tolerating thymine, but
destabilizing if confronted to an adenine as complementary base in the
antiparallel strand.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 8 OF 8 USPATFULL on STN
AN 1998:82883 USPATFULL
TI Antisense oligomers
IN Goodnow, Jr., Robert Alan, Basking Ridge, NJ, United States
Tam, Steve Yik-Kai, West Caldwell, NJ, United States
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)
PI US 5780607 19980714
AI US 1996-727685 19961008 (8)
PRAI US 1995-5689P 19951013 (60)
US 1996-22484P 19960809 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Marschel, Ardin H.; Assistant Examiner: Riley, Jezia
LREP Johnston, George W., Tramaloni, Dennis P., Kirk, Jr., Joseph P.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1856

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antisense oligomers of the formula ##STR1## wherein R.sub.1, R.sub.2 and
R.sub.4 are independently hydrogen, lower alkyl or acyl;

R.sub.3 is hydrogen or lower alkyl;

B is a nucleobase or a protected nucleobase, such that said oligomer has
a sequence of bases complementary to a selected RNA;

n is 5 to 30;

X is NR.sub.3 R.sub.4 ;

Y is OR.sub.3, or NHR.sub.3 ;

as well as, pharmaceutically acceptable salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.